Cargando…

A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1

BACKGROUND: Niemann-Pick disease type C1 (NPC1) is an autosomal-recessive lipid-storage disorder with an estimated minimal incidence of 1/120,000 live births. Besides other neuronal and visceral symptoms, NPC1 patients develop spleen dysfunction, isolated spleno- or hepatosplenomegaly and infections...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neßlauer, Anna-Maria, Gläser, Anne, Gräler, Markus, Engelmann, Robby, Müller-Hilke, Brigitte, Frank, Marcus, Burstein, Christine, Rolfs, Arndt, Neidhardt, John, Wree, Andreas, Witt, Martin, Bräuer, Anja U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598286/ https://www.ncbi.nlm.nih.gov/pubmed/31248418 http://dx.doi.org/10.1186/s12944-019-1088-2

Ejemplares similares

Corneal Alterations during Combined Therapy with Cyclodextrin/Allopregnanolone and Miglustat in a Knock-Out Mouse Model of NPC1 Disease
por: Hovakimyan, Marine, et al.
Publicado: (2011)

Miglustat in Niemann-Pick disease type C patients: a review
por: Pineda, Mercè, et al.
Publicado: (2018)

Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1
por: Yergey, Alfred L., et al.
Publicado: (2017)

Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-ß-cyclodextrin
por: Palladino, Giampiero, et al.
Publicado: (2015)

Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C
por: Héron, Bénédicte, et al.
Publicado: (2012)

New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat
por: Wraith, James E, et al.
Publicado: (2009)

Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann–Pick-Disease Type C1
por: Ebner, Lynn, et al.
Publicado: (2018)

Correction: Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1
por: Yergey, Alfred L., et al.
Publicado: (2018)

Normalisation of brain spectroscopy findings in Niemann–Pick disease type C patients treated with miglustat
por: Sedel, Frédéric, et al.
Publicado: (2016)

Effects of intracerebroventricular administration of 2-hydroxypropyl-β-cyclodextrin in a patient with Niemann–Pick Type C disease
por: Matsuo, Muneaki, et al.
Publicado: (2014)

2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1
por: Calias, Pericles
Publicado: (2017)

Longitudinal assessment of reflexive and volitional saccades in Niemann-Pick Type C disease during treatment with miglustat
por: Abel, Larry A., et al.
Publicado: (2015)

Favorable outcomes following early onset oral miglustat in early infantile Niemann Pick Type C
por: Curelaru, Shiri, et al.
Publicado: (2021)

Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect
por: Nadjar, Yann, et al.
Publicado: (2018)

Early detection of Niemann-pick disease type C with cataplexy and orexin levels: continuous observation with and without Miglustat
por: Imanishi, A., et al.
Publicado: (2020)

The Effects of Combined Therapy With Metformin and Hydroxypropyl-β-Cyclodextrin in a Mouse Model of Niemann-Pick Disease Type C1
por: Du, Jiang, et al.
Publicado: (2022)

Increased Regenerative Capacity of the Olfactory Epithelium in Niemann–Pick Disease Type C1
por: Meyer, Anja, et al.
Publicado: (2017)

Defects in the retina of Niemann-pick type C 1 mutant mice
por: Yan, Xin, et al.
Publicado: (2014)

Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C
por: Fecarotta, Simona, et al.
Publicado: (2015)

Olfactory Deficits in Niemann-Pick Type C1 (NPC1) Disease
por: Hovakimyan, Marina, et al.
Publicado: (2013)

Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1
por: Holzmann, Carsten, et al.
Publicado: (2021)

Efficacy and ototoxicity of different cyclodextrins in Niemann–Pick C disease
por: Davidson, Cristin D., et al.
Publicado: (2016)

Current Challenges in Understanding the Cellular and Molecular Mechanisms in Niemann–Pick Disease Type C1
por: Bräuer, Anja U., et al.
Publicado: (2019)

Influence of Npc1 genotype on the toxicity of hydroxypropyl-β-cyclodextrin, a potentially therapeutic agent, in Niemann–Pick Type C disease models()
por: Tanaka, Yuta, et al.
Publicado: (2014)

Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat
por: Walterfang, Mark, et al.
Publicado: (2012)

Use of miglustat in a child with late-infantile-onset Niemann-Pick disease type C and frequent seizures: a case report
por: Skorpen, Johannes, et al.
Publicado: (2012)

Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry
por: Patterson, Marc C., et al.
Publicado: (2020)

Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann–Pick C1 mutant cell via lysosome-associated membrane protein 1
por: Singhal, Ashutosh, et al.
Publicado: (2018)

Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice
por: Schlegel, Victoria, et al.
Publicado: (2016)

Long‐term survival outcomes of patients with Niemann‐Pick disease type C receiving miglustat treatment: A large retrospective observational study
por: Patterson, Marc C., et al.
Publicado: (2020)

Different Trafficking Phenotypes of Niemann-Pick C1 Gene Mutations Correlate with Various Alterations in Lipid Storage, Membrane Composition and Miglustat Amenability
por: Brogden, Graham, et al.
Publicado: (2020)

Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study
por: Freihuber, Cécile, et al.
Publicado: (2023)

Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis
por: Hastings, Caroline, et al.
Publicado: (2019)

Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease Type C: an international, multicenter, retrospective chart review
por: Pineda, Mercedes, et al.
Publicado: (2019)

Enhanced Human Tissue Microdialysis Using Hydroxypropyl-ß-Cyclodextrin as Molecular Carrier
por: May, Marcus, et al.
Publicado: (2013)

Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study
por: Patterson, Marc C, et al.
Publicado: (2015)

Pluronic based β-cyclodextrin polyrotaxanes for treatment of Niemann-Pick Type C disease
por: Collins, Christopher J., et al.
Publicado: (2017)

A phase 1/2 open label nonrandomized clinical trial of intravenous 2-hydroxypropyl-β-cyclodextrin for acute liver disease in infants with Niemann-Pick C1
por: Reynolds, Margaret, et al.
Publicado: (2021)

Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann–Pick Disease Type C Model Mice
por: Fukaura, Madoka, et al.
Publicado: (2021)

Linear Cyclodextrin Polymer Prodrugs as Novel Therapeutics for Niemann-Pick Type C1 Disorder
por: Kulkarni, Aditya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i6khf4biecg6a1dnqfjj3skdre